尊敬的各位投资者资本市场的各位朋友们大家下午好欢迎各位参加中国新联信有限公司2024年中期业绩发布会本次业绩的推介材料可于chinaxlx.com.hk下载出席本次发布会的管理层代表有执行董事兼总裁张庆津先生 执行董事兼副董事长闫韵华女士以及集团战略规划总监徐豪女士今天的会议议程如下首先由投资者关系总监申敬坤先生向大家介绍公司2024年中期业绩情况和公司基本概况 ...

证券研究报告 退市新规下，如何系统性识别上 市公司风险——规范篇 郑雅斌（金融工程首席分析师）SAC号码：S0850511040004 卓洢萱 （联系人） 2024年08月20日 内容要点： • 规范类风险警示 • 披露不合规 • 内部控制 • 公司重整 • 银行账户冻结 • 风险提示 2 请务必阅读正文之后的信息披露和法律声明 1. 规范类风险警示 规范类风险警示 银行账户 冻结 披露不合规内部控制公司重整 重大披露缺 陷 无法表示意见或否定意见 内控审计报告 控制权无序 争夺 未按期披露 因信息披露或者 规范运作等方面 存在重大缺陷， 被交易所限期改 正但公司未在规 定期限内改正， 公司股票自前述 期限届满的次一 交易日起停牌， 此后公司在股票 停牌2个月内仍 未改正。 未在法定期限内 披露半年度报告 或者经审计的年 度报告，公司股 票自前述期限届 满的次一交易日 起停牌，此后公 司在股票及其衍 生品种停牌2个 月内仍未披露 法院依法受 理公司重整、 和解和破产 清算申请。 （新） 主要银行账 户被冻结。 （新） 最近一个会计年 度财务报告内部 控制被出具无法 表示意见或否定 意见的审计报告。 连续2个会 ...

Financial Performance and Key Metrics - The company achieved sales revenue of RMB 460 million in the first half of 2024, with a gross margin of approximately 28% [1] - The gross margin for the leather business was 31%, while the gross margin for microfiber was 17%, and PU leather was 5% [1] - The gross margin for the main business increased from 29.5% in Q1 to 30.8% in Q2 [1] Business Line Performance - In Q2, the leather business revenue was approximately RMB 150 million, accounting for 70% of total revenue, while microfiber revenue was RMB 67 million, accounting for 30% [2] - The improvement in microfiber gross margin was due to scale effects and internal cost improvements [2] - PU leather revenue was RMB 1.6 million, and by-product revenue was RMB 25 million [2] Market Performance - The top five customers accounted for 23%, 15%, 13%, 10%, and around 5% respectively, with a shift from joint venture brands to domestic brands [3] - The new energy vehicle business accounted for 65% of revenue, with an expected growth rate of 70% in the second half of the year [4] Strategic Direction and Industry Competition - The company plans to transfer some orders from the Liaoning factory to Jiangsu to achieve cost reduction and efficiency improvement [5] - The Mexico factory, targeting the North American non-leather material market, is expected to achieve sales of RMB 150-200 million in 2024 and RMB 700 million by 2028 [5] Management Commentary on Operating Environment and Future Outlook - The company expects the gross margin for leather to remain above 30%, with potential pressure from customer price reductions [12] - The gross margin for microfiber is expected to be between 20% and 25%, while microfiber suede is expected to be between 35% and 37% [12] Other Important Information - The company is developing economical microfiber suede materials to reduce customer costs, with prices expected to drop from RMB 150-180 to around RMB 120 [28] Q&A Session Q: What is the revenue breakdown and gross margin change for leather and microfiber in H1 2024? - Total revenue in H1 2024 was RMB 467 million, with leather accounting for 73% and non-leather accounting for 26% [6] - The gross margin for leather was 31%, microfiber suede was 28.49%, suede was 35%, microfiber was 17%, and PU leather turned positive at 5% [6] Q: What is the specific breakdown of leather and microfiber in Q2? - In Q2, leather revenue was divided into cut pieces (RMB 100 million) and whole leather (RMB 50 million), while microfiber revenue was RMB 70 million, with suede and microfiber each accounting for RMB 35 million [7] Q: What is the gross margin for each business in Q2? - The gross margin for leather increased from 35% in Q1 to 36.64% in Q2, while cut pieces increased from 26.5% to 29% [8] - The gross margin for microfiber was 19.5%, suede was 38%, and PU leather turned positive at 11.5% [8] Q: What is the gross margin for waste materials? - The gross margin for waste materials was 7% in Q1, with prices fluctuating significantly with the market [9] Q: What is the outlook for future gross margins? - The gross margin for leather is expected to remain above 30%, with potential pressure from customer price reductions [12] - The gross margin for microfiber is expected to be between 20% and 25%, while microfiber suede is expected to be between 35% and 37% [12] Q: What is the future outlook for PU products? - The gross margin for PU products is expected to be around 15%, with the company focusing on market share despite low margins [13] Q: What is the revenue trend in Q2 and the impact of joint venture and domestic brands on gross margin? - Joint venture brands performed poorly, while domestic brands increased their share, with little change in overall gross margin [14] Q: What is the difference in payment terms between new energy and joint venture brands? - New energy business has longer payment terms and stricter repayment conditions compared to joint venture brands [15] Q: What is the revenue outlook for H2 and next year, and which key customers will drive growth? - New energy business is expected to grow by 70% in H2, with key customers including Huawei, XPeng, Chery, and Changan [15] Q: What is the impact of Li Auto and BYD on the company's performance? - Li Auto's platform adjustment affected performance, but recovery could significantly boost next year's performance [16] - BYD's cost reduction strategy impacted some projects, but the company remains a supplier for PU and PVC [16] Q: What is the company's overall performance expectation for 2024? - Revenue for 2023 was adjusted from RMB 1.3 billion to RMB 1.15 billion, with 2024 revenue expected to be between RMB 1.6 and 1.7 billion [16] Q: What are the specific projects and value for Li Auto and BYD? - Li Auto's L9 model has a value of over RMB 2000, while BYD's PU and PVC procurement platform accounts for 10-20% of the company's share [17] Q: What is the usage of leather and suede materials in BYD? - BYD uses leather and suede materials for high-end models, despite cost reduction strategies [18] Q: What is the usage of suede materials in Han EV and Tang EV models? - Han EV and Tang EV use suede materials in high-end models, with some usage remaining after price reductions [19] Q: What is the supply situation for Huawei's M9 model steering wheel and seats? - The company is the sole supplier for the M9 model steering wheel and a risk controller for seats, with significant supply volumes [20] Q: What is the supply situation for XPeng? - The company supplies leather and PU materials for XPeng's G9 and G6 models, with expectations for high sales [21] Q: What is the supply situation for Changan? - The company supplies leather materials for five Changan models, with significant contributions from the UNI-T, UNI-V, and Deep Blue series [22] Q: What is the progress of water-based polyurethane production and its impact on gross margin? - Water-based polyurethane is in small-scale production, with mass production expected in August, contributing to gross margin improvements [23] Q: What is the progress and characteristics of the Xinyi factory? - The Xinyi factory is expected to be operational by December 2024, with a focus on green and low-carbon production [24] Q: What is the production plan for Liaoning and Jiangsu factories? - The company plans to gradually adjust production between Liaoning and Jiangsu factories, with a focus on new energy customers in Jiangsu [24] Q: Will the product prices from Jiangsu factory be higher than those from Liaoning? - Initially, the company may offer price concessions to customers during the industrial adjustment period [25] Q: What is the progress of the Mexico factory and its targeted projects? - The Mexico factory was ready by June 30, targeting the North American non-leather material market, with certifications from Tesla, KIA, and Johnson [26] Q: What is the revenue expectation for the Mexico factory? - The Mexico factory is expected to achieve sales of RMB 150-200 million in 2024 and RMB 700 million by 2028 [27] Q: Is the company planning to develop economical microfiber suede materials? - The company is developing economical microfiber suede materials to reduce customer costs, with prices expected to drop from RMB 150-180 to around RMB 120 [28]

| --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------| | | | | 一、公司财务表现 | | | 公司披露中报，第二季度营收同比增长 25.84% ，规模同比增长 35% 45% 。 铅酸电池营收 60 亿元，同比增长 20.5% ，销量增长 17.1% 。 | ，扣费后同比增长 | | 低压锂电营收 1.2 亿元，同比增长 137% ，上半年亏损 5000 多万元。 再生铅外销同比下降，但二季度比一季度增长 108% ，上半年实现盈利。 ...

韦尔股份20240820_导读 2024年08月20日 22:49 关键词 韦尔股份 投资者 会议 声明 授权人 媒体转发 法律责任 主持人 方正电子 郑德江 51股份 威亚股份 营收 研 发投入 新产品 CIS 协同发展 核心管理团队 董事长 总经理 全文摘要 本次会议集中讨论了韦尔股份2024年上半年的业绩表现、技术创新与市场拓展情况。公司通过加大技术 投入，在图像传感器和自动驾驶解决方案等领域获得显著进展，推动了营业收入和毛利率的双增。同 时，公司注重产品结构调整和供应链优化，积极响应市场需求变化，积极布局新兴市场如互联网金融 和AR应用，以及在机器视觉和模拟解决方案等方面进行战略布局，以增强核心竞争力和促进未来业绩 增长。尽管面临市场竞争加剧和供应链挑战，公司展现出强大的适应和调整能力。销售和研发开支的增 加反映了公司在创新上的承诺，而财务状况的改善则展示了成本控制和效率提升的效果。展望未来，公 司对智能手机市场持乐观态度，并着重于新产品的开发，如AR眼镜，预期这些技术将为公司带来新的 增长动力。此外，公司还着眼于降低对特定半导体元件的依赖，以减轻潜在的风险。会议还探讨了显示 驱动业务面临的挑战，强调 ...

Financial Data and Key Metrics Changes - The clinical trial industry is showing positive development momentum due to increased support for medical innovation and improved market expectations [2][3] - The company has maintained its leading position in the domestic clinical pharmaceutical sector despite market fluctuations and client risk changes [4][10] Business Line Data and Key Metrics Changes - The company focuses on clinical research and has expanded its services to include clinical trial technology services and laboratory services, demonstrating strong performance in clinical applications and post-approval processes [4][20] - The company has accumulated over 3,500 clinical application project experiences, including more than 700 domestic first-class new drug clinical studies and over 120 global multi-center clinical studies [9] Market Data and Key Metrics Changes - The global biopharmaceutical industry is experiencing a rebound, with financing in the health sector showing a year-on-year growth trend, particularly in the biopharmaceutical and medical device sectors [6][16] - The domestic innovation support policies are continuously emerging, aiming to strengthen the development of the biopharmaceutical industry and optimize clinical trial approval processes [6][15] Company Strategy and Development Direction and Industry Competition - The company is expanding its business scope through both organic growth and mergers and acquisitions, consolidating its leadership position in the industry [2][7] - The company has established a global operational network and rich project experience, playing a crucial role in connecting domestic and international innovative products [2][9] Management's Comments on the Operating Environment and Future Outlook - Management noted that despite challenges such as demand slowdown, the main business continues to show steady growth, and performance is expected to improve with the recovery of the industry [10][12] - The management highlighted the importance of the company's strong market position and technical advantages in benefiting from the recovery of the clinical CRO industry [12][18] Other Important Information - The company has a strong talent pool, consisting of over 950 clinical research associates and more than 2,700 clinical coordinators, which contributes to its high revenue per capita [24] - The company has established a specialized fund to invest in early-stage enterprises in the biopharmaceutical and medical device fields, supporting innovation and development [23] Q&A Session Summary Question: What is the current position of the company in the global clinical CRO industry? - The company is a leading clinical trial service provider, having established extensive cooperation with clinical institutions in China and successfully expanded globally [11][18] Question: What are the signs of improvement in the clinical CRO industry, and how will the company benefit? - The clinical CRO industry is showing positive signs of recovery, with favorable policies and market conditions expected to enhance the company's performance [12][17] Question: What are the core business areas and advantages of the company? - The company primarily engages in clinical trial technology services and laboratory services, ensuring high-quality project delivery and accelerating the marketization of medical products [13][20] Question: How does the company assist domestic innovative drug companies in their international expansion? - The company serves as a crucial partner for domestic innovative drug companies looking to expand internationally, leveraging its expertise and understanding of client needs [21]

精达股份&恒丰特导20240819_1_导读 2024年08月20日 15:37 关键词 恒丰特导 DB200 精达股份 镀银铜线 高速线 铜温旅 母公司 提问时间 交流会 特导 加工费 市占率 认证 壁 垒 需求 特斯拉 新能源车 技术 铜线 铝线 全文摘要 本次讨论集中在丁达股份及其子公司恒丰特导的经营状况和发展前景上。丁达股份依托GV200产业链中 高市占率的优势地位，特别强调了DB200业务板块的重要性和未来增长潜力。恒丰特导在加工费用上 调、主营业务业绩超预期等方面表现出色，并在高速线领域看到了发展机遇。另一方观点则突出了特岛 公司在铜蓝导体材料及镀银铜线领域的技术优势及市场需求，以及其如何应对市场波动。公司凭借在高 速镀银铜线细分市场的高市占率，得益于专业的市场环境和严格的生产标准，稳固了其市场地位。同 时，讨论了加工费用对电子产品企业盈利能力的影响，以及市场需求变化对企业定价策略的影响。精达 股份通过采用扁线铜导体技术，在新能源汽车领域实现了业绩增长，并积极探索新技术以降低成本和满 足市场需求。恒丰科技依靠5000吨高速铜线业务和新能源车用铜扁线业务展望，预计明年净利润将达 到2亿。总体而言，通 ...

兆易创新 20240820_原文 2024 年 08 月 20 日 23:28 发言人 00:00 The meeting is ready to start. Please remain on the line. 发言人 00:17 感谢大家参加本次会议。会议即将开始，请稍后。Thanks for your participation. The meeting is ready to start. Please remain on the line. 发言人 00:43 感谢大家参加本次会议。会议即将开始，请稍后。Thanks for your participation. The meeting is ready to start. Please remain on the line. 发言人 01:08 感谢大家参加本次会议。各位投资者，大家晚上好，欢迎参加教育创新 2024 年中报投资者交流会。目前 所有参会者均处于静音状态，下面开始播报。免责声明，本次会议仅服务于邀请参会的广大投资者，会议 音频及文字记录的内容仅供参会者内部使用，不得公开发布。教育创新未授权任何媒体转发本次会议相关 内容，未经允许和 ...

鼎龙股份 20240820_原文 2024 年 08 月 20 日 23:27 发言人 00:00 人可直接发言，谢谢。本次会议为中国国际金融股份有限公司中金公司闭门会议，仅限受邀嘉宾参会。未 经中金公司和演讲嘉宾书面许可，任何机构和个人不得以任何形式将会议内容和相关信息对外公布、转发 转载、传播、复制、编辑、修改等。如有上述违法行为，中兴公司保留追究相关方法律责任的权利。This meeting is a close to door meeting of china international capital CoOperation limited C, I, C, C, and only invited, get allowed to attend without the written formation of C, I, C, C. And at the speaker, no organization or individual is allowed to punish forward, reprint, disseminate, copy, I did or modify the main com ...

泰格医药 20240820_原文 2024 年 08 月 20 日 23:27 发言人 00:00 很高兴今天给大家分享泰格医药的一个一个报告。然后首先的话，泰格医药其实已经是可能大家比较熟悉 的一家公司，是国内领先，然后也布局全球的一家临床 CO 的一个国内龙头企业。那经过 20 年的发展，整 个在国内的无论是临床机构的一个合作覆盖程度，还是说在成立以来为中国的一类创新药去提供服务的覆 盖度上。然后另外还是公从公司的这种全球扩张以及这种全科员工角度来说，是公司都已经成长到了一个 非常领先的一个临床医疗企业这样的一个地位。 发言人 00:39 目前其实我们整体从 CL 的一个行业情况可以看到，CO 行业其实相比可能过去两年稍微比较病理的一个状 态。目前是出现了不很多这样一个边际向好的一个迹象的那我们其实是可以去关注新奥公司相关的一个机 会。首先第一点就是的数据的一个管理点已经出现，包括像美国这个降息预期不断加强，其实以这个投融 资为这种前瞻指标导向的这样一个新药行业的一个景气度是有望复苏的。另外就是国内层层面创新的支持 政策是不断的，有一些新的一些利好出现。那对整个创新药剂的临床层面，以及创新药械这样一个上市 ...